YMAB Earnings

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

Published August 07, 2025 at 11:30 AM

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025.

Related Questions

What are the margins and cost trends reported for the quarter? Will the earnings release include any updates on FDA filings or regulatory milestones? Will there be any announcements of new partnerships, licensing deals, or collaborations? How will Y-mAbs' Q2 2025 earnings compare to consensus analyst estimates? Will the company provide updated guidance for FY 2025 and FY 2026? What are the projected revenue and net profit figures for Q2 2025? How might the earnings outcome affect short‑term trading strategies (e.g., options, volatility trades)? How have recent clinical trial results or pipeline updates affected expectations? How does the recent performance compare to peer biopharma companies in the antibody oncology space? Are there any notable changes in cash burn or cash runway that could affect liquidity? What is the expected impact on YMAB's share price volatility around the earnings release?